NasdaqGM - Delayed Quote USD

Astria Therapeutics, Inc. (ATXS)

Compare
11.46 -0.30 (-2.55%)
At close: October 18 at 4:00 PM EDT
11.46 0.00 (0.00%)
After hours: October 18 at 4:02 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Ms. Jill C. Milne Ph.D. Co-Founder, CEO, President & Director 938.78k -- 1968
Mr. Noah C. Clauser CPA CFO & Treasurer 621.41k -- 1974
Dr. Christopher J. Morabito M.D. Chief Medical Officer 661.57k -- 1970
Mr. Benjamin S. Harshbarger J.D. Chief Legal Officer 621.91k -- 1969
Ms. Keri McGrail Senior Vice President of Human Resources -- -- --
Ms. Andrea L. Matthews Chief Business Officer -- -- 1982
Mr. Andrew A. Komjathy Chief Commercial Officer -- -- 1963
Mr. John Ruesch Senior Vice President of Pharmaceutical Sciences & Technical Operations -- -- --

Astria Therapeutics, Inc.

75 State Street
Suite 1400
Boston, MA 02109
United States
617 349 1971 https://www.astriatx.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
59

Description

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Corporate Governance

Astria Therapeutics, Inc.’s ISS Governance QualityScore as of October 1, 2024 is 9. The pillar scores are Audit: 6; Board: 7; Shareholder Rights: 8; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 11, 2024 at 1:30 PM UTC - November 15, 2024 at 1:30 PM UTC

Astria Therapeutics, Inc. Earnings Date

Recent Events

August 12, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

June 6, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 9, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

April 22, 2024 at 12:00 AM UTC

DEF 14A: Proxy Statements

April 9, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 25, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 7, 2024 at 12:00 AM UTC

SC 13G/A: Tender Offer/Acquisition Reports

March 4, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 31, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 30, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers